Abstract
Background Earlier, we reviewed different methods of treating non-alcoholic fatty acid liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), concentrated on organokines liberated by adipose tissue (AT) and liver (adipoklines and hepatokines), adipokines in obesity with heart failure (HF), and myokines like irisin in exercise in obesity, and thought they might work as diagnostic and therapeutic targets in NAFLD and NASH with hepatocellular carcinoma (HCC). These are believed to be biological markers that can anticipate the robustness of NAFLD from NAFLD to HCC. Methods We conducted a narrative review utilizing search engines PubMed, Google Scholar; Web of Science; Embasee; Cochrane Library utilizing the MeSH terms “NAFLD”; “NASH”; “Organokines”; “Adipokines”; “Hepatokines”; “Myokines”; “Osteokines”; “Stellakines”; “Fructose”; “Gut Microbiota”; “Insulin resistance (IR)”; “Crosstalk of organokines”; “Obesity”; “T2D” from last 10-years till date in 2023. Results We found a total of 750 articles, out of which we selected 95 for this review. No meta-analysis has been done. Conclusion As acknowledged earlier, NAFLD possesses the characteristics of simple steatosis, while NASH progresses to hepatic steatosis, lobular inflammation, and an escalated diameter of hepatocytes (ballooning of hepatocytes) with or without fibrosis in 20% of cases of NAFLD. Usually, it is correlated with metabolic diseases like obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome (MetS); hence, the liberation of organokines gets manipulated in a way that might aid in the etiopathogenesis or propagation of disease. We observed that insulin resistance (IR), oxidative stress (OS), mitochondrial impairment, fructose, and gut microbiota reflected factors taking part in the development and propagation of NASH. Alterations in various organokines (inclusive of adipokines, hepatokines, myokines, osteokines, and a newer one, stellakines) produced by hepatic stellate cells (HSCs) were further seen to directly or indirectly aid in the exacerbation and propagation of disease or cause dysfunctional homeostasis. Moreover, we discuss the role of stellakines in detail, and targeting silymarin might give us an efficacious drug for the early treatment of NAFLD or NASH.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have